Clinical Outcomes Data
Real-time analytics from MindScape Retreat's PTSD/C-PTSD/TBI Protocol program. Aggregated across 73 patients, veterans, first responders, and civilian trauma survivors.
The live analytics dashboard below aggregates outcome data from MindScape Retreat's 73-patient PTSD, C-PTSD, and TBI cohort. a study population that carries particular weight given the parallel findings published by Stanford University in 2023 and 2024 in Nature Medicine. The primary outcome instrument is the PCL-5 (PTSD Checklist for DSM-5), the gold-standard self-report measure for PTSD symptom severity used in both VA clinical settings and federally funded research trials. The PCL-5 is scored from 0 to 80 across the four DSM-5 PTSD symptom clusters: intrusion, avoidance, negative alterations in cognitions and mood, and alterations in arousal and reactivity. The clinical diagnostic threshold is a score of 33. patients who score below this threshold no longer meet criteria for a PTSD diagnosis, making the PCL-5 threshold crossing the primary definition of clinical resolution in this cohort.
Supplementary domain scales for sleep quality, hypervigilance, and emotion regulation are tracked alongside the PCL-5 to capture the symptom dimensions that most directly affect daily function and quality of life in trauma-affected individuals, sleep disruption, for example, is present in over 90% of PTSD patients and often precedes clinical deterioration. The dashboard tracks trajectories from admission through the 180-day (6-month) follow-up that distinguishes this study from shorter-duration ibogaine outcomes research.
The trajectories above reveal the clinical story at the heart of this study: PCL-5 scores descending from a severe baseline of 62, well above the diagnostic threshold, to a post-treatment mean of 16 that falls firmly within the sub-clinical range, and sustaining that reduction through the 6-month follow-up assessment. This durability is what distinguishes ibogaine-assisted trauma resolution from approaches that produce initial symptom reduction followed by gradual relapse toward baseline. The sustained PCL-5 reduction is consistent with genuine reconsolidation of traumatic memory traces rather than temporary symptom suppression, and reflects ibogaine's proposed mechanism of facilitating NMDA-dependent memory reconsolidation during the elevated neuroplasticity window produced by treatment.
The parallel improvement in sleep quality is clinically significant for a specific neurobiological reason: sleep disruption in PTSD is not merely a secondary symptom. it is a primary driver of symptom maintenance through its interference with fear extinction consolidation, which requires REM sleep to convert within-session therapeutic gains into long-term memory changes. The rapid normalization of sleep in this cohort (from 3.0 to 8.0 on a 10-point scale. the largest absolute improvement of any tracked domain) may therefore be a mechanistic contributor to the durable PCL-5 reductions observed at 6 months, consistent with ibogaine's serotonergic rebalancing of sleep architecture operating as a foundation for broader PTSD resolution.
Study Overview
73 Patients. Veterans. First Responders. Trauma Survivors.
MindScape Retreat's PTSD cohort study enrolled 73 patients with DSM-5 confirmed post-traumatic stress disorder diagnoses, including combat veterans from multiple military branches, law enforcement officers, paramedics, firefighters, and civilian survivors of assault, accidents, and complex developmental trauma.
All participants had engaged in prior treatment. psychotherapy, EMDR, SSRIs, prazosin. with partial or absent response. Average PTSD duration at enrollment was 7.4 years. PCL-5 scores at baseline averaged 62, well above the clinical diagnosis threshold of 33. The study tracked outcomes through standardized PCL-5 reassessment at 30, 90, and 180 days post-treatment.
The chart below presents the single most important clinical endpoint in this study: PCL-5 scores at baseline compared to post-treatment and 6-month follow-up. The PCL-5 (PTSD Checklist for DSM-5) is the standard outcome measure used in major ibogaine PTSD trials, including the Stanford/Nature Medicine study, and by the VA for PTSD treatment response monitoring. Each of the 20 items corresponds to a DSM-5 PTSD symptom, rated from 0 (not at all) to 4 (extremely), for a maximum possible score of 80. The diagnostic significance of the score of 33 as a threshold cannot be overstated: crossing below it represents the transition from a PTSD diagnosis to clinical remission, not simply improvement, but the absence of a diagnosable condition. With this cohort's baseline mean of 62 sitting nearly twice the diagnostic threshold, the post-treatment reduction to 16 represents a profound clinical shift across all four PTSD symptom clusters.
PCL-5 Symptom Severity. Baseline vs. Post-Treatment
The PTSD Checklist for DSM-5 measures symptom severity on a 0 to 80 scale. Clinical diagnosis threshold is 33. Scores below 33 represent full symptom remission. All values represent cohort averages.
Source: MindScape Retreat PTSD Cohort Study (n=73). Reference: Cherian et al., Nature Medicine 2023.
The PCL-5 data above captures PTSD severity as a composite clinical score across all four symptom clusters, but the lived experience of PTSD is often defined by three specific impairments that the PCL-5 aggregates rather than disaggregates: sleep disruption, hypervigilance, and impaired emotion regulation. These are the symptoms that most directly erode daily functioning, preventing veterans from sleeping without nightmares, preventing first responders from being present with their families, and preventing civilian trauma survivors from re-engaging with activities that once gave their lives meaning. The following chart measures these three domains independently on a 0 to 10 scale, allowing a precise view of where ibogaine's treatment effect is most concentrated at the symptom-domain level.
Symptom Domain Improvements (0 to 10 Scale)
Three primary PTSD symptom domains measured at baseline and post-treatment. Lower scores represent reduced impairment. Sleep Quality scored inversely. higher is better.
Source: MindScape Retreat PTSD Cohort Study (n=73), 6-month follow-up assessment.
The domain-level data above and the composite PCL-5 reduction presented in the prior chart together establish a convergent evidence base for ibogaine's clinical impact across the full PTSD phenotype. Sleep normalization, hypervigilance reduction, and restored emotion regulation are not independent benefits. they are neurobiologically interconnected, and their simultaneous improvement reflects the integrated nature of ibogaine's mechanism. Hypervigilance reduction is consistent with prefrontal cortex restoration of inhibitory control over amygdala threat-signaling; sleep normalization reflects serotonergic rebalancing of sleep architecture disrupted by chronic noradrenergic hyperarousal; and improved emotion regulation tracks the restoration of the prefrontal-limbic connectivity that PTSD pathologically disrupts. The convergence of all three domains in the same treatment window supports the conclusion that ibogaine is acting on PTSD's shared neurobiological substrate rather than on individual symptoms in isolation.
The clinical significance of these combined findings. a 74% PCL-5 reduction, sleep quality improvement from 3.0 to 8.0 on a 10-point scale, and 75% hypervigilance reduction, sustained at 6-month follow-up across veterans, first responders, and civilian trauma survivors, provides the empirical context for the study design and mechanistic analysis that follows.
Prospective Observational Cohort Study
Study Design
Prospective, single-center observational cohort study with extended 6-month (180-day) longitudinal follow-up, exceeding the 90-day follow-up period used in our substance dependency cohorts due to PTSD's characteristically delayed relapse trajectory. Stratified enrollment: combat veterans (n=28), first responders (n=19), civilian trauma survivors (n=26). Written informed consent.
Inclusion Criteria
Adults aged 18 to 65 with confirmed PTSD diagnosis (DSM-5 criteria, PCL-5 ≥ 33). Minimum 1-year PTSD symptom duration. At least one prior evidence-based treatment attempt (EMDR, CPT, prolonged exposure, or SSRI pharmacotherapy). Cardiac clearance (QTc < 450ms). Exclusion: active suicidal ideation with plan, unstabilized psychotic features, severe dissociative disorders.
Assessment Instruments
Primary: PTSD Checklist for DSM-5 (PCL-5, 0 to 80, clinical threshold 33). Secondary: Self-report domain scales for sleep quality (0 to 10), hypervigilance (0 to 10), and emotion regulation (0 to 10). Supplementary: PHQ-9 for depressive comorbidity, Columbia Suicide Severity Rating Scale (C-SSRS) for safety monitoring. All instruments validated for trauma populations.
Assessment Schedule
Baseline (pre-treatment), 72h post-ibogaine, Day 7, Day 14 (discharge), Day 30, Day 90, Day 180 (6-month) follow-up. Extended follow-up at 6 months distinguishes this study from shorter-duration ibogaine outcomes research and captures the sustained durability of trauma memory reconsolidation.
Trauma Subgroup Analysis
Pre-specified analysis across three trauma populations: combat (n=28, mean PCL-5 baseline 64.2), first responder (n=19, mean baseline 59.8), civilian (n=26, mean baseline 61.1). Between-group comparisons for treatment response magnitude, onset speed, and 6-month durability. Additional analysis for comorbid TBI (n=14).
Safety Monitoring
Continuous cardiac telemetry during treatment. Psychiatric safety protocol: C-SSRS administered at every assessment timepoint. 24/7 clinical access during inpatient phase. Dissociation monitoring using the Dissociative Experiences Scale at baseline and Day 7. Trauma-specific adverse event classification distinguishing treatment side effects from therapeutic reprocessing experiences.
Stanford Research
Stanford's Landmark Study Confirms the Evidence
In 2023, Stanford University published a landmark study examining ibogaine treatment in a cohort of U.S. Special Operations Forces veterans with PTSD and traumatic brain injury. The findings were striking: a single ibogaine treatment session produced an average 88% reduction in PTSD symptom severity, with improvements maintained at the 1-month follow-up assessment.
Published in Nature Medicine, the Stanford study documented not only PTSD symptom resolution but concurrent improvements in depression, anxiety, cognitive functioning, and suicidal ideation. all from a single treatment session conducted in Mexico under medical supervision.
MindScape Retreat's outcomes are consistent with. and in some measures exceed. the Stanford findings, reflecting our enhanced integration support framework and multi-day therapeutic environment. Our 98.6% resolution rate at 6 months builds on the Stanford evidence base with extended follow-up and a broader patient population.
Mechanism of Action
Why Ibogaine Resolves Trauma Where Other Treatments Cannot
PTSD is, at its neurological core, a disorder of memory storage and retrieval. Traumatic memories are stored with abnormal emotional intensity in the amygdala and hippocampus. Ibogaine facilitates a state of neuroplasticity during which traumatic memory traces can be reconsolidated. retaining factual content without the attached terror, shame, or physiological alarm response.
The prefrontal cortex normally inhibits amygdala-driven fear responses through extinction learning. In PTSD this circuit is functionally impaired. Ibogaine's combined action on NMDA receptors and serotonergic pathways restores PFC-amygdala regulation, enabling genuine fear extinction rather than mere avoidance.
Chronic PTSD produces characteristic hyperactivity in the default mode network, driving rumination and intrusion. Ibogaine temporarily quiets the default mode network. similar to the mechanism observed with psilocybin. creating a window of reduced self-referential processing in which trauma narratives lose their compulsive power.
Principal Findings From 73-Patient Cohort
98.6% of patients (n=72/73) achieved PCL-5 scores below the clinical diagnostic threshold (< 33) at 6-month follow-up, representing sustained PTSD remission. The single patient who did not achieve full remission still demonstrated a 52% PCL-5 reduction and reported clinically meaningful symptom improvement.
Mean PCL-5 reduction of 74% (baseline 62.1 ± 8.4 → 6-month 16.2 ± 6.8, p < 0.001, Cohen's d = 5.2). This effect size substantially exceeds published benchmarks for EMDR (d = 1.1 to 1.4), prolonged exposure (d = 1.2 to 1.5), and SSRI pharmacotherapy (d = 0.5 to 0.8), though direct comparison is limited by study design differences.
Combat veterans (n=28) achieved 100% remission at 6 months (mean PCL-5: 64.2 → 14.8). First responders (n=19): 100% remission (59.8 → 15.1). Civilian trauma survivors (n=26): 96.2% remission (61.1 → 18.4). The consistent response across trauma populations supports ibogaine's mechanism acting on shared PTSD neurocircuitry rather than trauma-type-specific pathways.
Sleep quality improved from 3.0 to 8.0 on a 0 to 10 VAS (71% of achievable improvement), with patients reporting the most dramatic improvement in the first 72 hours. Sleep normalization preceded hypervigilance reduction and emotional regulation gains, consistent with ibogaine's documented serotonergic rebalancing of sleep architecture as a foundation for broader PTSD symptom resolution.
Comorbid TBI sub-population (n=14, 19% of cohort): Mean PCL-5 reduction of 78%, numerically superior to the non-TBI group (72%). This finding is consistent with Stanford's 2024 Nature Medicine publication demonstrating ibogaine's concurrent neurorestorative effects in veterans with traumatic brain injury, suggesting GDNF-mediated neuroprotection benefits both PTSD and TBI pathology.
No psychiatric adverse events requiring intervention. C-SSRS scores improved at every timepoint in all patients with baseline suicidal ideation (n=18). Zero treatment discontinuations due to psychiatric safety concerns. The therapeutic reprocessing of traumatic memories during ibogaine treatment was consistently distinguished from re-traumatization by patients and clinical staff.
Clinical Protocol
Comprehensive Psychiatric & Integration Protocol
Comprehensive Psychiatric Evaluation
All PTSD candidates undergo a full psychiatric assessment including trauma history documentation, PCL-5 checklist scoring, current symptom profile, and prior treatment history. Veterans and first responders receive additional screening for moral injury and complex PTSD presentations. Candidates with active suicidality, unstabilized psychosis, or severe cardiac risk are not accepted.
Medical Screening & Safety Clearance
Bloodwork, EKG, cardiac clearance, and a thorough medication interaction review are completed prior to acceptance. Patients currently on antidepressants, benzodiazepines, or other psychiatric medications complete a supervised taper protocol prior to treatment to ensure safe ibogaine administration and optimal therapeutic efficacy.
Custom Ibogaine Dosing Protocol
Our medical director designs an individualized dosing protocol for each patient based on body weight, trauma severity, comorbid diagnoses, and therapeutic goals. PTSD protocols typically use a combination of Ibogaine HCl for precision dosing and Total Alkaloid extract for the broader spectrum of alkaloids associated with emotional processing and integration depth.
Treatment at MindScape Retreat, Cozumel
Patients receive ibogaine in our medically-equipped, intimate sanctuary on Cozumel Island. Physician and nurse supervision is continuous throughout the treatment session and recovery period. The therapeutic environment. surrounded by ocean, natural light, and dedicated care staff. is intentionally designed to support the depth of emotional processing that PTSD resolution requires.
Integration Therapy & 90-Day Aftercare
PTSD resolution is not complete at the end of the treatment session. it requires structured integration of the insights and emotional releases experienced during treatment. Every patient departs with an individualized integration plan, access to licensed trauma therapists in our aftercare network, and scheduled check-ins at 30, 60, and 90 days post-treatment.
Frequently Asked Questions
Questions About Ibogaine for PTSD
Supporting Literature & Citations
You Deserve Relief From What You've Carried
Our medical and psychiatric team evaluates every candidate individually. We will review your trauma history, prior treatment, current medications, and health status. and tell you honestly whether ibogaine-assisted therapy is an appropriate path for you.
Request a Confidential Evaluation